Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study

To investigate the association between the extent of tapering tumor necrosis factor inhibitor (TNFi) and the likelihood of achieving inactive disease in patients with axial spondyloarthritis (axSpA) METHODS: We analyzed 1575 1-year follow-up interval data of 776 axSpA patients treated with TNFi for...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis research & therapy 2019-07, Vol.21 (1), p.163-163, Article 163
Main Authors: Park, Jun Won, Kim, Hyoun-Ah, Shin, Kichul, Park, Yong-Beom, Kim, Tae-Hwan, Song, Yeong Wook, Lee, Eun Young
Format: Article
Language:English
Subjects:
Ankylosing spondylitis
Arthritis
Cancer treatment
Care and treatment
Cohort analysis
Dosage and administration
Dose tapering
Drug dosages
Health aspects
Inactive disease
Medical prognosis
Necrosis
Patient outcomes
Patients
Physicians
Spondylitis
Spondyloarthritis
Task forces
TNF inhibitors
Tumor necrosis factor
Tumor necrosis factor inhibitors
Tumor necrosis factor-TNF
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the association between the extent of tapering tumor necrosis factor inhibitor (TNFi) and the likelihood of achieving inactive disease in patients with axial spondyloarthritis (axSpA) METHODS: We analyzed 1575 1-year follow-up interval data of 776 axSpA patients treated with TNFi for more than 1 year in a nationwide observational cohort. The decision on tapering TNFi was made by patients and their physicians. We quantified TNFi used during interval as a dose quotient (DQ). The intervals were classified into the heavy-tapering (DQ
ISSN:1478-6362
1478-6354
1478-6362
DOI:10.1186/s13075-019-1943-6